- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Ovarian Cancer | Clinical
Salani Reviews Role of PARP Inhibition in Ovarian Cancer
November 24, 2022
During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.
FDA Approves Mirvetuximab CDx to Identify Patients With Epithelial Ovarian Cancer
November 15, 2022
The new VENTANA FOLR1 RxDx Assay has been approved by the FDA and will aid in identifying patients with ovarian cancer who are eligible for targeted treatment with mirvetuximab soravtansine.
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
November 14, 2022
Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
Dosing and Toxicity: Managing Adverse Events and Dose Reductions for PARP Inhibitors in Ovarian Cancer
November 11, 2022
During a Targeted Oncology case-based roundtable event, Bradley J. Monk, MD, discussed recommendations for managing toxicity and dosing of PARP inhibitors as primary maintenance for ovarian cancer.
Mirvetuximab Shows Potential as New Standard of Care for FRα-Expressing Ovarian Cancer
November 08, 2022
In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discussed the pooled analysis of 3 studies which examined single agent mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
MEDIOLA Highlights Importance of BRCA Testing in Advanced Ovarian Cancer
November 07, 2022
In an interview with Targeted Oncology, Susana K. Banerjee, PhD, further discussed the updated results of the MEDIOLA trial and the implications of these findings.
Mirvetuximab Soravtansine Shows Continued Promise as Monotherapy in FRα+ Reccurent Ovarian Cancer
November 01, 2022
A pooled analysis of 3 studies showed that there was an extended treatment benefit for patients with FRα positive recurrent ovarian cancer treated with the novel antibody-drug conjugate mirvetuximab soravtansine.
CBX-12 Shows Antitumor Activity and Safety in Solid Tumors
October 31, 2022
In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.
Further Results from SOLO2 Underscore Need for New Strategies to Treat BRCA1/2+ Recurrent Epithelial Ovarian Cancer
October 27, 2022
Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.
Rucaparib Extends PFS in Deleterious BRACA1/2-Mutated Relapsed Ovarian Cancer
October 23, 2022
Amit M. Oza, MD, discusses progression-free survival findings from the phase 3 ARIEL4 clinical trial.